Name:	O
___.	O
Unit	O
No:	O
___	O
Admission	O
Date:	O
___	O
Discharge	O
Date:	O
___	O
Date	O
of	O
Birth:	O
___	O
Sex:	O
M	O
Service:	O
MEDICINE	O
Allergies:	O
Patient	O
recorded	O
as	O
having	O
No	O
Known	O
Allergies	O
to	O
Drugs	O
Attending:	O
___	O
Chief	O
Complaint:	O
Dyspnea	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure:	O
None	O
History	O
of	O
Present	O
Illness:	O
___	O
yo	O
M	O
with	O
COPD	O
on	O
O2	O
2L	O
NC	O
at	O
home,	O
tracheomalacia	O
with	O
recent	O
Y	O
stent	O
placement	O
on	O
___	O
by	O
IP,	O
CHF	O
(EF	O
45%),	O
afib	O
on	O
coumadin,	O
DM2,	O
HTN,	O
HLD,	O
p/w	O
5	O
days	O
of	O
progressively	O
worsening	O
productive	O
cough	O
of	O
brownish	O
sputum,	O
increased	O
O2	O
demand	O
to	O
3	O
liters	O
at	O
home,	O
subjective	O
fevers/chills.	O
CXR	O
with	O
bibasilar	O
opacities,	O
atelectasis	O
vs.	O
PNA.	B-Lower_respiratory_tract_infection
He	O
states	O
worsening	O
DOE	O
(baseline	O
___	O
staircase	O
now	O
only	O
3	O
stairs).	O
Pt	O
stopped	O
metolosone	O
approximately	O
one	O
week	O
ago.	O
.	O
In	O
the	O
ED,	O
initial	O
VS:	O
97.9	O
___	O
171/73	O
20	O
98%	O
4L.	O
He	O
was	O
given	O
a	O
first	O
dose	O
of	O
Levoquin.	O
.	O
ROS:	O
Denies	O
night	O
sweats,	O
headache,	O
vision	B-Visual_impairment
changes,	B-Visual_impairment
rhinorrhea,	O
congestion,	O
sore	O
throat,	O
cough,	O
chest	O
pain,	O
abdominal	O
pain,	O
nausea,	O
vomiting,	O
diarrhea,	O
constipation,	B-Constipation
BRBPR,	B-Lower_gastrointestinal_haemorrhage
melena,	B-Upper_gastrointestinal_haemorrhage
hematochezia,	B-Lower_gastrointestinal_haemorrhage
dysuria,	O
hematuria.	O
Past	O
Medical	O
History:	O
TBM	O
COPD	O
on	O
home	O
oxygen	O
2	O
L.	O
N/C	O
CHF,	O
last	O
echo	O
(EF	O
~45%)	O
DM	O
HLP	O
HTN	O
A-fib,	O
on	O
Coumadin	O
BPH	O
Melanoma	O
involving	O
right	O
eye	O
Nephrolithiasis	O
Social	O
History:	O
___	O
Family	O
History:	O
Non-contributory	O
Physical	O
Exam:	O
Vitals	O
-	O
T:	O
98.1	O
BP:	O
154/90	O
HR:87	O
RR:22	O
02	O
sat:95	O
GENERAL:	O
WD/WN,	O
in	O
NAD	O
HEENT:	O
NC/AT,	O
right	O
eye	B-Visual_impairment
enucleated	B-Visual_impairment
___	O
melanoma,	O
MMM	O
CARDIAC:	O
___,	O
nl	O
S1/S2	O
LUNG:	O
Bibasilar	O
rales,	O
intermittent	O
inspiratory	O
stridor	O
ABDOMEN:	O
Soft/NT/ND/NABS	O
EXT:	O
bilat	O
2+	O
pitting	O
___	O
edema	O
to	O
hips	O
NEURO:	O
CN	O
II-XII	O
intact,	O
MAE	O
Pertinent	O
Results:	O
___	O
11:35AM	O
WBC-12.0*#	O
RBC-4.12*	O
HGB-11.6*	O
HCT-36.6*	O
MCV-89	O
MCH-28.1	O
MCHC-31.6	O
RDW-15.6*	O
___	O
11:35AM	O
NEUTS-85.7*	O
LYMPHS-8.5*	O
MONOS-4.1	O
EOS-1.5	O
BASOS-0.2	O
___	O
11:35AM	O
GLUCOSE-131*	O
UREA	O
N-15	O
CREAT-1.0	O
SODIUM-140	O
POTASSIUM-4.0	O
CHLORIDE-97	O
TOTAL	O
CO2-36*	O
ANION	O
GAP-11	O
___	O
08:15PM	O
___	O
PTT-32.7	O
___	O
___	O
11:47AM	O
LACTATE-2.0	O
___	O
EKG:	O
Atrial	O
fibrillation.	O
Inferior	O
and	O
lateral	O
ST-T	O
wave	O
changes	O
are	O
non-specific.	O
Compared	O
to	O
the	O
previous	O
tracing	O
of	O
___	O
findings	O
are	O
similar.	O
___	O
CXR:	O
Left	O
lower	O
lobe	O
pneumonia,	B-Lower_respiratory_tract_infection
small	O
left	O
effusion,	O
stable	O
loculated	O
right	O
pleural	O
effusion,	O
cardiomegaly.	O
___	O
CXR:	O
In	O
comparison	O
with	O
the	O
study	O
of	O
___,	O
there	O
is	O
persistent	O
opacification	O
at	O
the	O
left	O
base	O
consistent	O
with	O
the	O
clinical	O
diagnosis	O
of	O
pneumonia	B-Lower_respiratory_tract_infection
and	O
effusion.	O
The	O
loculated	O
right	O
pleural	O
effusion	O
is	O
decreasing	O
in	O
size.	O
The	O
degree	O
of	O
pneumomediastinum	O
has	O
substantially	O
decreased.	O
Midline	O
sternal	O
wires	O
remain	O
in	O
place.	O
___	O
TTE:	O
The	O
right	O
atrium	O
is	O
moderately	O
dilated.	O
No	O
atrial	O
septal	O
defect	O
is	O
seen	O
by	O
2D	O
or	O
color	O
Doppler.	O
There	O
is	O
mild	O
symmetric	O
left	O
ventricular	O
hypertrophy.	O
The	O
left	O
ventricular	O
cavity	O
is	O
mildly	O
dilated.	O
There	O
is	O
mild	O
regional	O
left	O
ventricular	O
systolic	O
dysfunction	O
with	O
basl	O
inferior	O
hypokinesis.	O
There	O
is	O
no	O
ventricular	O
septal	O
defect.	O
The	O
right	O
ventricular	O
cavity	O
is	O
moderately	O
dilated	O
with	O
mild	O
global	O
free	O
wall	O
hypokinesis.	O
The	O
aortic	O
valve	O
leaflets	O
(3)	O
are	O
mildly	O
thickened	O
but	O
aortic	O
stenosis	O
is	O
not	O
present.	O
No	O
aortic	O
regurgitation	O
is	O
seen.	O
The	O
mitral	O
valve	O
leaflets	O
are	O
mildly	O
thickened.	O
Mild	O
(1+)	O
mitral	O
regurgitation	O
is	O
seen.	O
The	O
tricuspid	O
valve	O
leaflets	O
are	O
mildly	O
thickened.	O
There	O
is	O
moderate	O
pulmonary	O
artery	O
systolic	O
hypertension.	O
There	O
is	O
no	O
pericardial	O
effusion.	O
___	O
CXR:	O
No	O
new	O
acute	O
cardiopulmonary	O
process.	O
Persistent	O
but	O
imrproving	O
left	O
lower	O
lobe	O
opacity,	O
improved	O
compared	O
to	O
___.	O
Small	O
pleural	O
effusions	O
are	O
also	O
decreasing.	O
Brief	O
Hospital	O
Course:	O
___	O
male	O
with	O
history	O
of	O
tracheobronchomalacia,	O
COPD	O
(2L	O
NC	O
home	O
O2	O
requirement),	O
congestive	O
heart	O
failure	O
(EF	O
50%),	O
diabetes	O
mellitus	O
type	O
II,	O
atrial	O
fibrillation	O
on	O
coumadin,	O
melanoma	O
presents	O
with	O
likely	O
pneumonia,	B-Lower_respiratory_tract_infection
CHF	O
and	O
COPD	B-Lower_respiratory_tract_infection
exacerbation.	B-Lower_respiratory_tract_infection
#	O
Pneumonia:	B-Lower_respiratory_tract_infection
The	O
patient	O
presented	O
with	O
left	O
lower	O
lobe	O
pneumonia	B-Lower_respiratory_tract_infection
on	O
chest	O
x-ray.	O
He	O
had	O
an	O
increased	O
O2	O
requirement	O
to	O
4L	O
NC	O
(from	O
2L	O
NC	O
at	O
home).	O
The	O
patient	O
was	O
treated	O
with	O
a	O
7-day	O
course	O
of	O
levofloxacin.	O
Blood	O
cultures	O
were	O
negative.	O
His	O
white	O
count	O
and	O
symptoms	O
improved.	O
The	O
cough	O
was	O
persistent	O
though	O
improving	O
at	O
time	O
of	O
discharge.	O
The	O
patient	O
remained	O
afebrile	O
and	O
his	O
oxygen	O
requirement	O
returned	O
to	O
normal.	O
The	O
patient	O
will	O
need	O
a	O
follow	O
up	O
chest	O
x-ray	O
in	O
___	O
weeks	O
to	O
ensure	O
resolution.	O
#	O
Acute	O
on	O
chronic	O
congestive	O
heart	O
failure:	O
The	O
patient	O
presented	O
with	O
evidence	O
of	O
gross	O
hypervolemia.	O
The	O
patient	O
had	O
a	O
TTE	O
which	O
showed	O
an	O
EF	O
of	O
50%	O
(for	O
full	O
report	O
please	O
see	O
OMR).	O
The	O
patients	O
respiratory	O
status	O
improved	O
greatly	O
after	O
diuresis.	O
The	O
patient	O
was	O
started	O
on	O
torsemide	O
20mg	O
PO	O
daily	O
with	O
maintained	O
hypovolemia.	O
While	O
he	O
was	O
inpatient	O
his	O
I/Os	O
and	O
weights	O
were	O
closely	O
monitored.	O
He	O
was	O
also	O
continued	O
on	O
lisinopril	O
and	O
metoprolol	O
succinate.	O
He	O
will	O
need	O
close	O
monitoring	O
as	O
an	O
outpatient	O
to	O
ensure	O
that	O
20mg	O
of	O
torsemide	O
is	O
the	O
proper	O
diuretic	O
dose.	O
#	O
Chronic	O
obstructive	O
pulmonary	O
disease:	O
The	O
patient	O
has	O
a	O
recent	O
worsening	O
of	O
his	O
pulmonary	O
process.	O
He	O
carries	O
a	O
diagnosis	O
of	O
chronic	O
obstructive	O
disease.	O
He	O
is	O
on	O
2L	O
NC	O
at	O
home.	O
Initially	O
he	O
required	O
4L	O
NC	O
to	O
maintain	O
SaO2,	O
however	O
this	O
was	O
weaned	O
with	O
the	O
above	O
treatments.	O
Pulmonary	O
was	O
consulted	O
and	O
recommended	O
prednisone	O
50mg	O
PO	O
x5	O
with	O
no	O
taper.	O
The	O
patient	O
got	O
this	O
medication	O
and	O
felt	O
much	O
improved.	O
The	O
patient	O
was	O
also	O
maintained	O
on	O
Advair	O
inhaler,	O
albuterol	O
nebs	O
and	O
tiotropium	O
inhaler.	O
The	O
patient	O
was	O
discharged	O
on	O
resting	O
2L	O
NC	O
O2	O
sat	O
and	O
ambulatory	O
4L	O
NC	O
O2	O
sat.	O
#	O
Atrial	O
fibrillation:	O
The	O
patient	O
has	O
a	O
diagnosis	O
of	O
atrial	O
fibrillation.	O
He	O
is	O
rate	O
controlled	O
on	O
metoprolol	O
tartrate.	O
His	O
dose	O
of	O
metoprolol	O
tartrate	O
was	O
decreased	O
to	O
25mg	O
BID	O
while	O
in	O
the	O
hospital.	O
He	O
does	O
become	O
bradycardic	O
at	O
times	O
but	O
remained	O
asymptomatic.	O
He	O
was	O
discharged	O
on	O
metoprolol	O
succinate.	O
The	O
patient	O
was	O
maintained	O
on	O
warfarin	O
with	O
an	O
INR	O
goal	O
of	O
___.	O
His	O
INR	O
prior	O
to	O
discharge	O
was	O
subtherapeutic.	O
This	O
will	O
need	O
to	O
be	O
monitored	O
closely	O
with	O
adjustments	O
to	O
his	O
coumadin	O
dosing	O
as	O
needed.	O
#	O
Diabetes	O
mellitus	O
type	O
II:	O
The	O
patient	O
is	O
maintained	O
on	O
oral	O
agents	O
at	O
home.	O
He	O
was	O
maintained	O
on	O
an	O
insulin	O
sliding	O
scale	O
as	O
an	O
inpatient.	O
While	O
he	O
was	O
on	O
prednisone	O
his	O
diabetes	O
was	O
poorly	O
controlled,	O
likely	O
secondary	O
to	O
steroid	O
effect.	O
He	O
will	O
be	O
continued	O
on	O
an	O
insulin	O
sliding	O
scale	O
while	O
at	O
rehab.	O
He	O
will	O
need	O
to	O
have	O
this	O
discontinued	O
and	O
be	O
restarted	O
on	O
his	O
oral	O
regimen	O
once	O
his	O
prednisone	O
is	O
complete.	O
Fingersticks	O
should	O
be	O
checked	O
at	O
rehab.	O
#	O
Hypertension:	O
The	O
patient	O
was	O
well	O
controlled	O
on	O
lisinopril	O
and	O
metoprolol	O
tartrate.	O
His	O
lisinopril	O
dose	O
was	O
increased	O
to	O
20mg	O
daily	O
and	O
his	O
metoprolol	O
tartrate	O
dose	O
was	O
decreased	O
to	O
25mg	O
BID.	O
This	O
should	O
be	O
followed	O
as	O
an	O
outpatient	O
to	O
ensure	O
adequate	O
blood	O
pressure	O
control.	O
#	O
Hypochloremic	O
metabolic	O
alkalosis:	O
This	O
was	O
likely	O
secondary	O
to	O
aggresive	O
diuresis	O
as	O
an	O
inpatient.	O
The	O
patient	O
received	O
multiple	O
doses	O
of	O
acetazolamide.	O
This	O
was	O
monitored	O
with	O
labs	O
and	O
improved	O
by	O
discharge.	O
#	O
Hyperlipidemia:	O
The	O
patient	O
was	O
continued	O
on	O
resuvastatin	O
5mg	O
PO	O
qhs.	O
Medications	O
on	O
Admission:	O
Flomax	O
0.4mg	O
Lexapro	O
5mg	O
Crestor	O
5mg	O
Niacin	O
500mg	O
BID	O
Lasix	O
120mg	O
daily	O
Metoprolol	O
Tartrate	O
50mg	O
BID	O
Warfarin	O
5mg	O
___	O
7.5mg	O
M/W	O
Mag-Oxide	O
Glipizide	O
mucinex	O
___	O
BID	O
celexa	O
20mg	O
daily	O
metolazone	O
2.5mg	O
daily	O
advair	O
spireva	O
Discharge	O
Medications:	O
1.	O
Flomax	O
0.4	O
mg	O
Capsule,	O
Sust.	O
Release	O
24	O
hr	O
Sig:	O
One	O
(1)	O
Capsule,	O
Sust.	O
Release	O
24	O
hr	O
PO	O
at	O
bedtime.	O
2.	O
Lexapro	O
5	O
mg	O
Tablet	O
Sig:	O
One	O
(1)	O
Tablet	O
PO	O
once	O
a	O
day.	O
3.	O
Crestor	O
5	O
mg	O
Tablet	O
Sig:	O
One	O
(1)	O
Tablet	O
PO	O
once	O
a	O
day.	O
4.	O
Niacin	O
500	O
mg	O
Tablet	O
Sig:	O
One	O
(1)	O
Tablet	O
PO	O
twice	O
a	O
day.	O
5.	O
Magnesium	O
Oxide	O
140	O
mg	O
Capsule	O
Sig:	O
Two	O
(2)	O
Capsule	O
PO	O
BID	O
(2	O
times	O
a	O
day).	O
6.	O
Toprol	O
XL	O
25	O
mg	O
Tablet	O
Sustained	O
Release	O
24	O
hr	O
Sig:	O
One	O
(1)	O
Tablet	O
Sustained	O
Release	O
24	O
hr	O
PO	O
once	O
a	O
day.	O
Disp:*30	O
Tablet	O
Sustained	O
Release	O
24	O
hr(s)*	O
Refills:*0*	O
7.	O
Warfarin	O
2.5	O
mg	O
Tablet	O
Sig:	O
as	O
directed	O
Tablet	O
PO	O
once	O
a	O
day:	O
Please	O
use	O
as	O
directed	O
(take	O
2	O
tabs	O
on	O
___,	O
___	O
and	O
___,	O
take	O
3	O
tabs	O
on	O
___.	O
Tablet(s)	O
8.	O
Glipizide	O
5	O
mg	O
Tablet	O
Sig:	O
One	O
(1)	O
Tablet	O
PO	O
once	O
a	O
day:	O
please	O
start	O
once	O
ISS	O
is	O
stopped.	O
9.	O
Albuterol	O
Sulfate	O
90	O
mcg/Actuation	O
HFA	O
Aerosol	O
Inhaler	O
Sig:	O
Two	O
(2)	O
puffs	O
Inhalation	O
every	O
four	O
(4)	O
hours	O
as	O
needed	O
for	O
shortness	O
of	O
breath	O
or	O
wheezing.	O
10.	O
Advair	O
Diskus	O
250-50	O
mcg/Dose	O
Disk	O
with	O
Device	O
Sig:	O
One	O
(1)	O
Inhalation	O
once	O
a	O
day.	O
11.	O
Lisinopril	O
20	O
mg	O
Tablet	O
Sig:	O
One	O
(1)	O
Tablet	O
PO	O
DAILY	O
(Daily).	O
Disp:*30	O
Tablet(s)*	O
Refills:*0*	O
12.	O
Aspirin	O
81	O
mg	O
Tablet,	O
Chewable	O
Sig:	O
One	O
(1)	O
Tablet,	O
Chewable	O
PO	O
DAILY	O
(Daily).	O
13.	O
Citalopram	O
20	O
mg	O
Tablet	O
Sig:	O
One	O
(1)	O
Tablet	O
PO	O
DAILY	O
(Daily).	O
14.	O
Mucinex	O
1,200	O
mg	O
Tab,	O
Multiphasic	O
Release	O
12	O
hr	O
Sig:	O
One	O
(1)	O
Tab,	O
Multiphasic	O
Release	O
12	O
hr	O
PO	O
twice	O
a	O
day.	O
15.	O
Omeprazole	O
20	O
mg	O
Capsule,	O
Delayed	O
Release(E.C.)	O
Sig:	O
One	O
(1)	O
Capsule,	O
Delayed	O
Release(E.C.)	O
PO	O
BID	O
(2	O
times	O
a	O
day).	O
Disp:*60	O
Capsule,	O
Delayed	O
Release(E.C.)(s)*	O
Refills:*0*	O
16.	O
Torsemide	O
20	O
mg	O
Tablet	O
Sig:	O
One	O
(1)	O
Tablet	O
PO	O
DAILY	O
(Daily).	O
Disp:*30	O
Tablet(s)*	O
Refills:*0*	O
17.	O
Acetylcysteine	O
20	O
%	O
(200	O
mg/mL)	O
Solution	O
Sig:	O
One	O
(1)	O
ML	O
Miscellaneous	O
Q6H	O
(every	O
6	O
hours)	O
as	O
needed	O
for	O
cough.	O
18.	O
oxygen	O
order	O
diagnosis:	O
COPD	O
Please	O
use	O
2L	O
NC	O
when	O
stationary.	O
Please	O
use	O
4L	O
NC	O
with	O
activity.	O
19.	O
Prednisone	O
50	O
mg	O
Tablet	O
Sig:	O
One	O
(1)	O
Tablet	O
PO	O
once	O
a	O
day	O
for	O
2	O
days.	O
Disp:*2	O
Tablet(s)*	O
Refills:*0*	O
20.	O
Docusate	O
Sodium	O
100	O
mg	O
Capsule	O
Sig:	O
One	O
(1)	O
Capsule	O
PO	O
BID	O
(2	O
times	O
a	O
day)	O
as	O
needed	O
for	O
constipation.	B-Constipation
21.	O
Insulin	O
Lispro	O
100	O
unit/mL	O
Solution	O
Sig:	O
as	O
directed	O
Subcutaneous	O
four	O
times	O
a	O
day	O
for	O
2	O
days:	O
please	O
see	O
printed	O
insulin	O
sliding	O
scale	O
in	O
discharge	O
summary.	O
Please	O
stop	O
this	O
and	O
resume	O
oral	O
antiglycemics	O
once	O
finished	O
with	O
prednisone.	O
22.	O
Senna	O
8.6	O
mg	O
Tablet	O
Sig:	O
One	O
(1)	O
Tablet	O
PO	O
twice	O
a	O
day	O
as	O
needed	O
for	O
constipation.	B-Constipation
23.	O
Outpatient	O
Lab	O
Work	O
Please	O
check	O
INR	O
weekly,	O
adjust	O
coumadin	O
dose	O
prn	O
Discharge	O
Disposition:	O
Extended	O
Care	O
Facility:	O
___	O
Discharge	O
Diagnosis:	O
Primary	O
Diagnosis:	O
1.	O
CHF	O
exacerbation	O
2.	O
Pneumonia	B-Lower_respiratory_tract_infection
Secondary	O
Diagnosis:	O
1.	O
COPD	O
2.	O
TBM	O
s/p	O
Y-stent	O
3.	O
Hypertension	O
4.	O
Atrial	O
fibrillation	O
Discharge	O
Condition:	O
Mental	O
Status:	O
Clear	B-Delirium
and	B-Delirium
coherent	B-Delirium
Level	O
of	O
Consciousness:	O
Alert	O
and	O
interactive	O
Activity	O
Status:	O
Ambulatory	B-Independently_mobile
-	B-Independently_mobile
Independent	B-Independently_mobile
Discharge	O
Instructions:	O
You	O
were	O
admitted	O
with	O
a	O
pneumonia	B-Lower_respiratory_tract_infection
and	O
CHF	O
exacerbation.	O
Your	O
CHF	O
was	O
treated	O
with	O
IV	O
diuretics.	O
You	O
were	O
then	O
transitioned	O
to	O
PO	O
diuretics.	O
You	O
were	O
given	O
an	O
antibiotic	O
for	O
your	O
pneumonia.	B-Lower_respiratory_tract_infection
You	O
were	O
feeling	O
better	O
and	O
were	O
back	O
on	O
your	O
home	O
oxygen	O
requirement.	O
You	O
were	O
also	O
started	O
on	O
a	O
short	O
dose	O
of	O
steroids.	O
This	O
has	O
elevated	O
your	O
blood	O
sugars	O
and	O
you	O
were	O
started	O
on	O
an	O
insulin	O
sliding	O
scale.	O
This	O
should	O
be	O
stopped	O
when	O
you	O
are	O
done	O
with	O
your	O
prednisone	O
and	O
you	O
should	O
resume	O
your	O
oral	O
antiglycemics.	O
You	O
were	O
discharged	O
on	O
toresemide	O
and	O
will	O
need	O
labs	O
drawn	O
to	O
follow	O
your	O
INR	O
in	O
___	O
days	O
and	O
have	O
your	O
coumadin	O
adjusted.	O
You	O
will	O
alos	O
need	O
to	O
get	O
your	O
INR	O
checked	O
weekly	O
after	O
that.	O
You	O
will	O
follow	O
up	O
with	O
your	O
primary	O
care	O
physician	O
once	O
you	O
are	O
discharged	O
from	O
rehab.	O
The	O
following	O
changes	O
were	O
made	O
to	O
your	O
medications:	O
1.	O
START	O
torsemide	O
20mg	O
by	O
mouth	O
daily	O
2.	O
STOP	O
lasix	O
3.	O
START	O
omeprazole	O
20mg	O
by	O
mouth	O
twice	O
daily	O
4.	O
START	O
metoprolol	O
succinate	O
25mg	O
by	O
mouth	O
daily	O
5.	O
STOP	O
metoprolol	O
tartrate	O
6.	O
INCREASE	O
Lisinopril	O
20mg	O
by	O
mouth	O
daily	O
7.	O
START	O
Prednisone	O
50mg	O
by	O
mouth	O
for	O
2	O
days	O
8.	O
START	O
ISS	O
while	O
on	O
prednisone	O
at	O
rehab	O
Followup	O
Instructions:	O
___	O

